NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 20.96 against a street estimate of 18.30 — a beat of 14.5%.
with an average price target of ₹2,497.27.
CONFIDENT Glenmark delivered 23.1% YoY consolidated revenue growth in Q1 FY'27, driven by India outperformance, strong North America respiratory launches, and emerging market momentum. Margins pressured by geopolitical costs but management expects 21–22% guidance intact. Q1 FY'27 Broad-based growth except Europe, which is intentionally transitioning to branded portfolio. North America respiratory launches driving recovery. Emerging markets and India outperforming. Analysts pressed on India concentration risk (Telma dominance), Europe slowdown timing, and injectable monetization. Management dismissed concentration risk, confirmed branded pivot drives Europe recovery, and clarified injectables are immaterial near-term but build from Monroe facility next year. R&D and litigation provisions largely settled. 2026-08-03…
Full summary in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Glenmark Pharmaceuticals Limited — free to start.
Google PlayApp StoreData updated 2026-08-05.